<DOC>
	<DOCNO>NCT02836548</DOCNO>
	<brief_summary>This mono-center open-label proof-of-concept pharmacologic study explore efficacy safety vorinostat advance BRAF mutate melanoma , become resistant BRAF-inhibitors combination BRAF- MEK-inhibitors .</brief_summary>
	<brief_title>HDAC Inhibitor Vorinostat Resistant BRAF V600 Mutated Advanced Melanoma</brief_title>
	<detailed_description>Activating mutation BRAF gene present 50 % human melanoma . BRAF inhibitor ( BRAFi ) inhibit serine-threonine protein kinase BRAF , play dominant role MAPK pathway influence cell growth . MEK inhibitor ( MEKi ) inhibit MEK1 MEK2 , two regulatory protein downstream BRAF . The clinical benefit treatment limit due development drug resistance 6-8 month treatment BRAFi 9-14 month treatment BRAFi combination MEKi.This often associate secondary mutation MAPK pathway lead re-activation pathway.Withholding treatment BRAFi and/or MEKi lead reversible hyperactivation MAPK pathway , cause transient growth arrest . Chronic proliferation growth arrest occur persistent hyperactivation MAPK pathway . Treatment BRAFi and/or MEKi resistant melanoma vorinostat , histone deacetylase inhibitor ( HDACi ) , lead persistent hyperactivation pathway state growth arrest hallmarks oncogene induced senescence.In study mice BRAFi resistant BRAF V600 mutate melanoma switch BRAFi HDACi vorinostat result complete disappearance tumor two month treatment . HDACi cause accumulation Reactive Oxygen Species ( ROS ) lead apoptosis upregulation MAPK-pathway . As see Wang et al hyperactivation MAPK-pathway important milestone anti-tumor treatment BRAF V600 melanoma . This phase I , single-center , single-arm , non-randomized , open-label , clinical pharmacological proof principal study determine safety vorinostat anti-tumor therapy patient advance resistant BRAF V600 mutate melanoma . A total 21 evaluable patient BRAF V600 mutate melanoma develop resistance BRAFi and/or BRAFi+MEKi least 4 week PR CR response enrol study . Vorinostat give single daily dose 360 mg derive establish register dose treatment cutaneous T-cell lymphoma . Treatment continuous cycle 28 day dos reduce step 90 mg per dose-reduction case unacceptable safety concern .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>1 . Histological proof advance melanoma BRAF V600 mutation ; 2 . Progression disease , accord RECIST 1.1 , treatment BRAFi , vemurafenib dabrafenib ; combination BRAF MEK inhibitor , trametinib dabrafenib ; 3 . Previous document response ( partial complete ) least 4 week treatment BRAFi and/or BRAFi+MEKi ; 4 . Start vorinostat treatment within maximum period 1 week discontinuation BRAFi and/or BRAFi+MEKi . The BRAFi and/or BRAFi+MEKi continue progression provide sufficient time perform baseline assessment ; 5 . Age ≥ 18 year ; 6 . Able willing give write informed consent ; 7. WHO performance status 0 , 1 2 ; 8 . Able willing undergo blood sample PK PD analysis ; 9 . Life expectancy ≥ 3 month allow adequate follow toxicity evaluation antitumor activity ; 10 . Evaluable disease accord RECIST 1.1 ; 11 . Minimal acceptable safety laboratory value ANC ≥ 1.5 x 109 /L Platelet count ≥ 100 x 109 /L Hemoglobin ≥ 6.0 mmol/L Hepatic function define serum bilirubin ≤ 1.5 x ULN , ALAT ASAT ≤ 2.5 x ULN , case liver metastasis ALAT ASAT ≤ 5 x ULN Renal function define serum creatinine ≤ 1.5 x ULN creatinine clearance ≥ 50 ml/min ( CockcroftGault formula , MDRD ) . 12 . Negative pregnancy test ( urine/serum ) within 72 hour receive first dose study medication female patient childbearing potential ; 13 . Able willing undergo fresh histological tumor sample prior start , upon treatment upon progression vorinostat . 1 . Any treatment investigational drug , except BRAFi MEKi , within 28 day prior receive first dose investigational treatment ; 21 day standard chemotherapy immunotherapy ; 2 . Patients previous treatment vorinostat HDAC inhibitor ; 3 . Leptomeningeal disease ; 4 . Symptomatic brain metastasis . Patients previously treat untreated condition and/or asymptomatic absence corticosteroid therapy allow enroll . Patients permit receive enzyme induce antiepileptic drug corticosteroid ; 5 . Clinical progression melanoma first week discontinuation BRAFi BRAFi/MEKi ; 6 . Woman pregnant breast feeding ; 7 . Unreliable contraceptive method . Both men woman enrol trial must agree use reliable contraceptive method screen 30 day last dose study medication ( adequate contraceptive method : oral inject implanted hormonal method contraception , condom , sterilization , barrier contraceptive measure preferably combination condom , true abstinence ) ; 8 . Radiotherapy within last 4 week prior receive first dose investigational treatment ; except 1x8 Gray pain palliation ; 9 . Uncontrolled infectious disease know Human Immunodeficiency Virus HIV1 HIV2 type patient ; 10 . Patients known history hepatitis B C ; 11 . Recent myocardial infarction ( &lt; 6 month receive first dose study medication ) unstable angina ;</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>advanced melanoma</keyword>
	<keyword>BRAF V600 mutation</keyword>
	<keyword>vorinostat</keyword>
	<keyword>HDAC inhibitor</keyword>
</DOC>